BioMarin upgraded to Buy from Hold at Stifel Nicolaus Stifel Nicolaus upgraded BioMarin based on valuation, and its belief that the company's pipeline may produce better than expected results in FY13. The firm also sees the company as an attractive acquisition target in the near-term. Target $67.
BioMarin price target raised to $104 from $90 at William Blair William Blair raised its price target for BioMarin shares to $104 following the company's R&D day and keeps an Outperform rating on the stock. The firm expects the Vimizim launch to remain strong and believes BioMarin holds one of the strongest pipelines in the sector.
Piper Jaffray biopharm analyst holds an analyst/industry conference call Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.